09552358-6d23-4990-858e-908ee5a132f6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- UV_RESPONSE_DN+0.400
- ANGIOGENESIS+0.300
- NOTCH_SIGNALING+0.300
- TGF_BETA_SIGNALING+0.300
- COAGULATION+0.200
- IL6_JAK_STAT3_SIGNALING+0.200
- PANCREAS_BETA_CELLS+0.200
- PROTEIN_SECRETION+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
Top 10 suppressed
- E2F_TARGETS-0.600
- MYC_TARGETS_V2-0.600
- G2M_CHECKPOINT-0.500
- INTERFERON_ALPHA_RESPONSE-0.300
- MTORC1_SIGNALING-0.300
- MYC_TARGETS_V1-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- INTERFERON_GAMMA_RESPONSE-0.200
- TNFA_SIGNALING_VIA_NFKB-0.200
- ADIPOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A1NH-01A-11R-A14D-07 | — | A | 0.839 |
| 2 | TCGA-HD-7831-01A-11R-2132-07 | — | — | 0.838 |
| 3 | TCGA-BH-A1FH-01A-12R-A13Q-07 | — | A | 0.830 |
| 4 | TCGA-AR-A24T-01A-11R-A169-07 | — | A | 0.822 |
| 5 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.815 |
| 6 | SRR8613790 | — | A | 0.810 |
| 7 | 102d912c-5882-4ae4-9eaf-cbd2f55f66af | — | — | 0.810 |
| 8 | SRR5088898 | — | — | 0.809 |
| 9 | SRR12202434 | — | — | 0.800 |
| 10 | TCGA-A1-A0SH-01A-11R-A084-07 | — | A | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |